Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:41:38.752Z.
Calculation as of: 2026-10-06T22:41:38.752Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$693.61M
EV/Sales Ratio
5.65x
TTM Avg
15.51x
3Y Avg
12.72x
5Y Avg
18.09x
Market Cap
$691.79M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$694.79M
EV/Sales Ratio
3.13x
TTM Avg
2.70x
3Y Avg
2.97x
5Y Avg
5.54x
Market Cap
$685.49M
EV/Sales Ratio
192.43x
TTM Avg
133.47x
3Y Avg
94.21x
5Y Avg
94.21x
Market Cap
$681.27M
EV/Sales Ratio
N/A
TTM Avg
2.20x
3Y Avg
6.98x
5Y Avg
6.98x
Market Cap
$709.65M
EV/Sales Ratio
1.78x
TTM Avg
2.74x
3Y Avg
3.00x
5Y Avg
3.08x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $693.19M | N/A | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | 5.65x | 15.51x | 12.72x | 18.09x |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | 3.13x | 2.70x | 2.97x | 5.54x |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | 192.43x | 133.47x | 94.21x | 94.21x |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A | 2.20x | 6.98x | 6.98x |
| Verastem, Inc. (VSTM)vs › | $681.02M | 7.19x | 41.09x | 46.52x | 55.30x |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 1.78x | 2.74x | 3.00x | 3.08x |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 1.52x | 1.59x | 2.50x | 2.28x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
